ClinicalTrials.gg
CompletedNCT03625466Updated Nov 2, 2022Results posted

A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

A Phase 2 interventional study of LUM/IVA and LUM/IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 5 sites in Germany. Open to participants aged 2 Years to 5 Years. Per ClinicalTrials.gov, last updated 2022-11-02.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
2 Years to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.

Enrollment
15th of 20
51 · median 66
Started
2018
with 1 other
Phase 2
4 of 20
none open now
Registered
19th of 20
by date
Lead sponsor
20 of 20
Vertex Pharmaceuticals Incorporated

Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 15th largest by enrollment, is one of 2 that started in 2018, is one of 4 in phase 2, and was the 19th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →

About lumacaftor

lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 2 Years to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing lumacaftor in Cystic Fibrosis as a file.
02

Study summary

This study will explore the impact of lumacaftor/ivacaftor (LUM/IVA) on disease progression in subjects aged 2 through 5 years with cystic fibrosis (CF), homozygous for F508del (F/F).

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
2 Years to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Subjects with confirmed diagnosis of CF.
  • Homozygous for F508del (F/F).
  • Subjects who weigh ≥8 kg without shoes and wearing light clothing at the Screening Visit.

Key Exclusion Criteria:

  • Any laboratory abnormalities at the Screening Visit that would interfere with the study assessments or pose an undue risk for the subject.
  • Solid organ or hematological transplantation.
  • History of any illness or comorbidity reviewed at the Screening Visit that, in the opinion of the investigator, might confound the results of the study.

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
51 participants (actual)

Study arms

  • Placebo comparator
    Part 1: Placebo

    Participants received placebo matched to LUM/IVA in placebo-controlled period for 48 weeks.

    Drug: Placebo

  • Experimental
    Part 1: LUM/IVA

    Participants weighing less than (\<)14 kilograms (kg) at screening received LUM 100 milligrams (mg)/IVA 125 mg fixed-dose combination (FDC) every 12 hours (q12h) in placebo-controlled period for 48 weeks. Participants weighing greater than or equals to (\>=)14 kg at screening received LUM 150 mg/IVA 188 mg FDC q12h in placebo-controlled period for 48 weeks.

    Drug: LUM/IVA

  • Experimental
    Part 2: Overall LUM/IVA

    Participants who received either placebo or LUM/IVA in placebo-controlled period administered LUM/IVA (either LUM 100 mg/IVA 125 mg FDC q12h or LUM 150 mg/IVA 188 mg FDC q12h as per their body weight for participants \<6 years of age at week 48 and LUM 200 mg/IVA 250 mg FDC q12h regardless of their body weight for participants \>=6 years of age at week 48) in open-label period for 48 weeks.

    Drug: LUM/IVA

Interventions

  • DrugLUM/IVA

    Drug pages: Lumacaftor · Ivacaftor

    FDC tablets or granules for oral administration.

    Also known as: Lumacaftor/Ivacaftor, VX-809/VX-770

  • DrugLUM/IVA

    Drug pages: Lumacaftor · Ivacaftor

    FDC granules for oral administration.

    Also known as: Lumacaftor/Ivacaftor, VX-809/VX-770

  • DrugPlacebo

    Placebo matched to LUM/IVA for oral administration.

06

What researchers measure

Primary outcomes

  1. Part 1: Absolute Change From Baseline in MRI Global Chest Score at Week 48

    MRI scans assessed semi-quantitatively via a standardized chest MRI scoring system. Each participant had 6 lobes scored using 7 scoring parameters:1) Bronchiectasis/wall thickening 2) Mucus plugging 3) Abscesses/sacculations 4) Consolidations 5) Special findings 6)Mosaic pattern 7) Perfusion abnormalities. For each of 7 parameter, there were scores of 6 lobes (score of each lobe : 0= normal value, 1 = \<50% of lobe involved and 2 = \>=50% of lobe involved). MRI global score was calculated as sum of parameters 1 to 7. MRI total score is ranged from 0-84. Higher score indicate more lobe involvement.

    Time frame: From Baseline at Week 48

Secondary outcomes

  1. Part 1: Absolute Change in Lung Clearance Index2.5 (LCI2.5) Through Week 48

    LCI2.5 represents the number of lung turnovers required to reduce the end-tidal inert gas concentration to 1/40th of its starting value.

    Time frame: From Baseline Through Week 48

  2. Part 1: Absolute Change in Weight-for-age Z-score at Week 48

    The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.

    Time frame: From Baseline at Week 48

  3. Part 1: Absolute Change in Stature-for-age Z-score at Week 48

    The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.

    Time frame: From Baseline at Week 48

  4. Part 1: Absolute Change in Body Mass Index (BMI)-For-age Z-score at Week 48

    BMI was defined as weight in kilogram (kg) divided by squared height in meters (m\^2). The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.

    Time frame: From Baseline at Week 48

07

Results

Posted Dec 8, 2021

Participant flow

This study was planned in 2 parts: Part 1 (Placebo-controlled Period) and Part 2 (Open-label Period). The primary and secondary efficacy analyses were planned for only Part 1.

Placebo-controlled Period (48 Weeks)
Participant flow — Placebo-controlled Period (48 Weeks)
MilestonePart 1: PlaceboPart 1: LUM/IVAPart 2: Overall LUM/IVA
Started16350
Completed16330
Not completed020
Withdrew: Adverse event010
Withdrew: Withdrawal of consent (not due to ae)010
Open-label Period (48 Weeks)
Participant flow — Open-label Period (48 Weeks)
MilestonePart 1: PlaceboPart 1: LUM/IVAPart 2: Overall LUM/IVA
Started0049
Completed0048
Not completed001
Withdrew: Withdrawal of consent (not due to ae)001

Outcome measures

PrimaryPart 1: Absolute Change From Baseline in MRI Global Chest Score at Week 48

MRI scans assessed semi-quantitatively via a standardized chest MRI scoring system. Each participant had 6 lobes scored using 7 scoring parameters:1) Bronchiectasis/wall thickening 2) Mucus plugging 3) Abscesses/sacculations 4) Consolidations 5) Special findings 6)Mosaic pattern 7) Perfusion abnormalities. For each of 7 parameter, there were scores of 6 lobes (score of each lobe : 0= normal value, 1 = \<50% of lobe involved and 2 = \>=50% of lobe involved). MRI global score was calculated as sum of parameters 1 to 7. MRI total score is ranged from 0-84. Higher score indicate more lobe involvement.

Time frame:
From Baseline at Week 48
Reported as:
Mean · score on a scale
Part 1: Absolute Change From Baseline in MRI Global Chest Score at Week 48
score on a scalePart 1: PlaceboPart 1: LUM/IVA
Part 1: Absolute Change From Baseline in MRI Global Chest Score at Week 48-0.3 ± 6.1-1.7 ± 6.6
Statistical analysis
  • Part 1: Placebo vs Part 1: LUM/IVA · Mean difference: -1.5 · 95% CI -5.5 to 2.6
SecondaryPart 1: Absolute Change in Lung Clearance Index2.5 (LCI2.5) Through Week 48

LCI2.5 represents the number of lung turnovers required to reduce the end-tidal inert gas concentration to 1/40th of its starting value.

Time frame:
From Baseline Through Week 48
Reported as:
Mean · lung clearance index
Part 1: Absolute Change in Lung Clearance Index2.5 (LCI2.5) Through Week 48
lung clearance indexPart 1: PlaceboPart 1: LUM/IVA
Part 1: Absolute Change in Lung Clearance Index2.5 (LCI2.5) Through Week 480.32 (-0.20 to 0.84)-0.37 (-0.85 to 0.10)
SecondaryPart 1: Absolute Change in Weight-for-age Z-score at Week 48

The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.

Time frame:
From Baseline at Week 48
Reported as:
Mean · z-score
Part 1: Absolute Change in Weight-for-age Z-score at Week 48
z-scorePart 1: PlaceboPart 1: LUM/IVA
Part 1: Absolute Change in Weight-for-age Z-score at Week 48-0.07 (-0.24 to 0.11)0.13 (-0.01 to 0.27)
SecondaryPart 1: Absolute Change in Stature-for-age Z-score at Week 48

The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.

Time frame:
From Baseline at Week 48
Reported as:
Mean · z-score
Part 1: Absolute Change in Stature-for-age Z-score at Week 48
z-scorePart 1: PlaceboPart 1: LUM/IVA
Part 1: Absolute Change in Stature-for-age Z-score at Week 480.10 (-0.04 to 0.24)0.09 (-0.05 to 0.22)
SecondaryPart 1: Absolute Change in Body Mass Index (BMI)-For-age Z-score at Week 48

BMI was defined as weight in kilogram (kg) divided by squared height in meters (m\^2). The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.

Time frame:
From Baseline at Week 48
Reported as:
Mean · z-score
Part 1: Absolute Change in Body Mass Index (BMI)-For-age Z-score at Week 48
z-scorePart 1: PlaceboPart 1: LUM/IVA
Part 1: Absolute Change in Body Mass Index (BMI)-For-age Z-score at Week 48-0.24 (-0.55 to 0.07)0.20 (-0.02 to 0.41)

Adverse events

Collected over From Day 1 up to Week 98 (Part 1: From Day 1 up to Week 48; Part 2: From Week 48 up to Week 98). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Placebo0/16 (0%)2/16 (12.5%)16/16 (100%)
Part 1: LUM/IVA0/35 (0%)7/35 (20%)33/35 (94.3%)
Part 2: Overall LUM/IVA0/49 (0%)12/49 (24.5%)41/49 (83.7%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPart 1: PlaceboPart 1: LUM/IVAPart 2: Overall LUM/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations1/163/353/49
Lung infiltrationRespiratory, thoracic and mediastinal disorders1/160/350/49
Sedation complicationInjury, poisoning and procedural complications0/160/352/49
HaematemesisGastrointestinal disorders0/161/350/49
IntussusceptionGastrointestinal disorders0/161/350/49
ConstipationGastrointestinal disorders0/161/350/49
PneumoniaInfections and infestations0/161/350/49
Coeliac diseaseGastrointestinal disorders0/160/351/49
Distal intestinal obstruction syndromeGastrointestinal disorders0/160/351/49
VomitingGastrointestinal disorders0/160/351/49
Most frequent other events
Showing 10 of 57
Most frequent other events
EventPart 1: PlaceboPart 1: LUM/IVAPart 2: Overall LUM/IVA
NasopharyngitisInfections and infestations8/1622/3519/49
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations9/1615/3511/49
RhinitisInfections and infestations6/169/358/49
CoughRespiratory, thoracic and mediastinal disorders5/1610/3511/49
Nasal congestionRespiratory, thoracic and mediastinal disorders4/160/358/49
Abdominal painGastrointestinal disorders2/167/356/49
PyrexiaGeneral disorders3/166/352/49
Upper respiratory tract infectionInfections and infestations3/161/352/49
Abdominal pain upperGastrointestinal disorders2/161/352/49
VomitingGastrointestinal disorders2/162/354/49

Baseline characteristics

Baseline population included all randomized participants who have received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Part 1: PlaceboPart 1: LUM/IVATotal
Mean4.2 ± 1.04.2 ± 1.04.2 ± 1.0
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: PlaceboPart 1: LUM/IVATotal
Female71118
Male92433
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: PlaceboPart 1: LUM/IVATotal
Hispanic or Latino000
Not Hispanic or Latino163551
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: PlaceboPart 1: LUM/IVATotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White163551
More than one race000
Unknown or Not Reported000
Magnetic Resonance Imaging (MRI) Global Chest Score
Magnetic Resonance Imaging (MRI) Global Chest Score(score on a scale)Part 1: PlaceboPart 1: LUM/IVATotal
Mean21.4 ± 9.317.6 ± 9.718.8 ± 9.6
08

Study locations

5 sites
  • Charite Paediatric Pulmonology Department
    Berlin, Germany
  • Justus-Leibig-Universitat Zentrum fur Kinderheilkunde und Jugendmedizin
    Giessen, Germany
  • Hannover Medical School
    Hannover, Germany
  • Heidelberg Cystic Fibrosis Center
    Heidelberg, Germany
  • Universitatsklinikum Schleswig-Holstein, Klinik für Kinder- und Jugendmedizin
    Lubeck, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Oct 2020, 25 months.

Results were first posted in Dec 2021, 1 year 1 month after primary completion.

Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 25 months is above that.

Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2018
First posted
Aug 10, 2018
StartActual
Aug 10, 2018
Primary completionActual
Oct 9, 2020
CompletionActual
Oct 7, 2021
Results first posted
Dec 8, 2021
Last update
Nov 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03625466
Responsible party
Sponsor
First posted
Aug 10, 2018
Start date
Aug 10, 2018
Primary completion
Oct 9, 2020
Completion
Oct 7, 2021
Results posted
Dec 8, 2021
Last update
Nov 2, 2022

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lumacaftor · Ivacaftor

Start the discussion